Opyl Ltd. (AU:OPL) has released an update.
Opyl Limited has announced a strategic non-exclusive partnership with Phenix Health to use its AI platform, TrialKey, for validating clinical trials of cannabis products listed on Phenix Health’s Compendium platform. This collaboration aims to support suppliers by providing research-backed validation reports, priced at $5,000 AUD each, to help them comply with regulations and gain a competitive advantage in the medicinal cannabis market. The agreement, which can be terminated with 30 days’ notice, underscores Opyl’s role in enhancing the reliability of clinical trials and medicinal cannabis products through advanced AI analytics.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.
